The expression of Egr-1 in breast and endometrial cancer cells is stimulated by E2 and hydroxytamoxifen (OHT) and mediated via GPER/EGFR/ERK signaling and in model cell lines (breast and endometrial cancer cells). Here, EGFR is linked to endometrial cancer.